|Assessment Status||Rapid review complete|
|Indication||In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.|
|Rapid review commissioned||12/08/2021|
|Rapid review completed||09/09/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that durvalumab not be considered for reimbursement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.